<DOC>
	<DOCNO>NCT01649856</DOCNO>
	<brief_summary>This multicenter , randomize , open label parallel-group study evaluate efficacy safety subcutaneous versus intravenous MabThera/Rituxan ( rituximab ) combination CHOP chemotherapy patient previously untreated CD20-positive diffuse large B-Cell lymphoma . Patients randomize receive either MabThera/Rituxan 1400 mg subcutaneously MabThera/Rituxan 375 mg/m2 intravenously Day 1 cycle 8 cycle , combination 6-8 cycle CHOP chemotherapy . Anticipated time study treatment 6 month .</brief_summary>
	<brief_title>A Study Subcutaneous Versus Intravenous MabThera/Rituxan ( Rituximab ) Combination With CHOP Chemotherapy Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 &lt; /= 80 year age time study inclusion Histologically confirm , previously untreated CD20positive diffuse large Bcell lymphoma ( DLBCL ) accord WHO classification system Patients International Prognostic Index ( IPI ) score 15 , IPI score 0 bulky disease , define one lesion &gt; /= 7.5 cm At least one bidimensionally measurable lesion define &gt; /= 1.5 cm large dimension CT scan , PETCT scan MRI Adequate hematologic function Eastern Cooperative Oncology Group ( EOCD ) performance status &lt; /= 2 Primary secondary central nervous system lymphoma , histologic evidence transformation Burkitt lymphoma , primary mediastinal DLBCL , primary effusion lymphoma , primary cutaneous DLBCL , primary DLBCL testis Transformed lymphoma follicular lymphoma IIIB Prior therapy DLBCL , exception nodal biopsy local irradiation History malignancy , except curatively treat basal squamous cell carcinoma melanoma skin , carcinoma situ cervix , malignancy treat without curative intent remission without treatment &gt; /= 5 year prior enrolment Inadequate renal hepatic function Known human immunodeficiency virus ( HIV ) infection HIV seropositive status Active hepatitis B virus ( HBV ) active hepatitis C virus ( HCV ) infection . Patients occult prior HBV infection define protocol may include . Patients positive HCV antibody eligible polymerase chain reaction test HCV ribonucleic acid negative . History severe allergic anaphylactic reaction humanize murine monoclonal antibody know sensitivity allergy murine product Contraindication individual component CHOP , include prior receipt anthracyclines Prior treatment cytotoxic drug rituximab another condition ( e.g . rheumatoid arthritis ) prior use antiCD20 antibody Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>